Diovan CHF Claim: Use As Substitute For ACE Inhibitor Supported By FDA
Executive Summary
FDA's "approvable" letter for Diovan in congestive heart failure suggests that existing data are sufficient to approve the drug as a substitute to ACE inhibitors, Novartis Pharmaceuticals Development Head Joerg Reinhardt told an Oct. 30 New York analysts meeting